Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amakem spins off from Devgen; brings in €1.5mm in seed money

Executive Summary

Devgen NV (now focused on crop enhancement technology) has spun off the assets and IP from its former pharma division into Amakem NV (respiratory and ophthalmic compounds). The newly formed company simultaneously raised €1.5mm ($2mm) in seed money from lead investor Lombard Risk Management (LRM), Life Sciences Research Partners, and Vlaams Innovatiefonds--Flemish Innovation Fund (VINNOF). Devgen will retain a 21% stake in Amakem.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies